Cite
Xing YJ, Liu BH, Wan SJ, et al. A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress . Front Pharmacol. 2021;12:708177doi: 10.3389/fphar.2021.708177.
Xing, Y. J., Liu, B. H., Wan, S. J., Cheng, Y., Zhou, S. M., Sun, Y., Yao, X. M., Hua, Q., Meng, X. J., Cheng, J. H., Zhong, M., Zhang, Y., Lv, K., & Kong, X. (2021). A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress . Frontiers in pharmacology, 12708177. https://doi.org/10.3389/fphar.2021.708177
Xing, Yu-Jie, et al. "A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress ." Frontiers in pharmacology vol. 12 (2021): 708177. doi: https://doi.org/10.3389/fphar.2021.708177
Xing YJ, Liu BH, Wan SJ, Cheng Y, Zhou SM, Sun Y, Yao XM, Hua Q, Meng XJ, Cheng JH, Zhong M, Zhang Y, Lv K, Kong X. A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress . Front Pharmacol. 2021 Jul 12;12:708177. doi: 10.3389/fphar.2021.708177. eCollection 2021. PMID: 34322029; PMCID: PMC8311522.
Copy
Download .nbib